Epinomics teams up with Parker’s I-O Institute for biomarker work

Researchers from Epinomics have penned a collaboration with the Parker Institute for Cancer Immunotherapy to use biomarkers from the company to help boost outcomes and lower adverse events in immunotherapy trials. The deal sees Epinomics work with the Institute’s director Crystal Mackall. The center was set up with funds from the Facebook and Napster billionaire Sean Parker, who is also funding what could be the first CRISPR trials in the U.S.

 “The insights from this work will serve to direct further improvements for these therapeutics that will be pursued at Stanford and the set of biomarkers will be employed in clinical use moving forward,” said Fergus Chan, who co-founded Epinomics back in 2013.